LncH19 regulates osteoclast activation by targeting miR-196a-5p to diagnose postmenopausal osteoporosis

Postmenopausal women have a higher prevalence of osteoporosis (OP) due to age related factors and hormonal changes. This study aims to investigate the interactions between lncH19 and miR-196a-5p, as well as their roles in the diagnosis and management of OP.

The ultimate goal is to identify novel biomarkers and potential therapeutic targets for this disease.

The relative expression levels of lncH19 and miR-196a-5p were measured using RT-qPCR. The diagnostic potential of lncH19 for OP was evaluated via receiver operating characteristic (ROC) curve analysis. The interaction between lncH19 and miR-196a-5p was verified by a luciferase reporter assay. To explore the regulatory effect of lncH19 in the pathogenesis of OP, PMA-induced THP-1 cells were used as an in vitro model.

In postmenopausal women with OP, serum lncH19 levels were decreased, whereas miR-196a-5p levels were increased, and the two exhibited a negative correlation. LncH19 showed significant clinical diagnostic value for OP. It was confirmed that lncH19 directly targets miR-196a-5p and can suppress PMA induced inflammatory responses in macrophages. However, miR-196a-5p mimics could attenuate the anti-inflammatory effect of lncH19.

This study provides new insights into the pathogenesis of OP, clarifies the important value of lncH19 as a predictive biomarker, and offers a new direction for the treatment and prognostic evaluation of OP.